Client Overview
The client is an Italy based pharmaceutical organization focused on biological products for orphan indications. The company was seeking US market access for its enzyme replacement therapies but lacked prior experience with BLA submissions for such specialized products.
Client Background
The client had initiated BLA filings with the US FDA but encountered Regulatory pushback regarding data sufficiency and manufacturing controls. A change in the drug product manufacturing site, which had never been inspected by the agency, added another layer of complexity.
Services in Scope
End to end BLA preparation and submission support for enzyme replacement therapies.
Regulatory submission strategy and planning, including a detailed submission planner.
Gap analysis and remediation of source documents and scientific data.
Coordination with multiple CMOs to gather, validate, and finalize required documentation.
Training and knowledge transfer to the client’s internal teams on BLA processes and future FDA interactions.
Challenges
Lack of in house expertise in BLA submissions for orphan biological products.
US FDA identification of insufficient scientific data within the existing application.
Added complexity from a change in drug product manufacturing site with no prior FDA inspection history.
Need for close coordination across several CMOs to secure complete and consistent source data.
Solution
Freyr established a structured BLA program that combined rigorous gap analysis, data consolidation, and step wise module preparation. The team functioned as the client’s extended Regulatory arm, owning the strategy, orchestrating CMO interactions, and ensuring that each BLA module met all FDA expectations.
1
Performed a detailed gap analysis of all source documents and scientific data to identify deficiencies against FDA standards for BLAs.
2
Coordinated with multiple CMOs to collect missing data, clarify inconsistencies, and secure the timely delivery of all supporting documents.
3
Prepared and finalized BLA modules and sections with complete, scientifically robust information tailored to FDA expectations for orphan disease therapies.
4
Developed a Regulatory submission strategy and planner, and trained client teams on the agreed Regulatory action plan to manage both current and future FDA queries.
Impact
- Zero FDA refusals of the BLAs for target enzyme replacement therapies.
- Successful preparation and submission of BLAs that led to US FDA approval for the products.
- Enhanced internal readiness through training, enabling the client to manage future FDA issues more independently.
The engagement turned a risky BLA situation into a successful pathway for orphan-disease therapies. By combining strategic Regulatory planning, module preparation, and CMO coordination, Freyr helped the client secure approvals and build Regulatory skills. The client is now more confident in expanding its biological portfolio in the US.
